Straits Times Index
3,293.13 +20.41 (+0.62%) S&P 500
5,064.35 -6.20 (-0.12%) Dow
38,376.63 -127.06 (-0.33%) Nasdaq
15,724.88 +28.24 (+0.18%) Bitcoin USD
64,965.92 -1,644.54 (-2.47%) CMC Crypto 200
1,403.03 -21.07 (-1.48%)
Roche Holding AG (ROG.SW)
| Previous close | 229.70 |
| Open | 226.60 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 220.60 - 226.70 |
| 52-week range | 217.00 - 293.55 |
| Volume | |
| Avg. volume | 1,457,503 |
| Market cap | 179.182B |
| Beta (5Y monthly) | 0.15 |
| PE ratio (TTM) | 15.52 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 9.60 (4.18%) |
| Ex-dividend date | 14 Mar 2024 |
| 1y target est | N/A |
- GlobeNewswire
[Ad hoc announcement pursuant to Art. 53 LR] Roche sales increase by 2% (CER) in first quarter with both divisions growing in high single digit ex COVID-19
Group sales grew by 2%1 at constant exchange rates (CER) (-6% in CHF), driven by the strong growth of newer medicines and diagnostics. Excluding COVID-19-related products, sales increased by 7%. Going forward, there will be no further material impact of COVID-19 sales declineDue to the appreciation of the Swiss franc against most currencies, sales were 6% lower when reported in CHFPharmaceuticals Division base business2 grew by 7%, driven by strong sales of medicines to treat severe diseases, su
- GlobeNewswire
FDA approves Roche’s Alecensa as the first adjuvant treatment for people with ALK-positive early-stage lung cancer
Approval based on Phase III ALINA study showing Alecensa reduced the risk of disease recurrence or death by an unprecedented 76% in people with ALK-positive early-stage resected non-small cell lung cancer (NSCLC)1This approval helps address an urgent unmet need, with about half of people living with early-stage NSCLC experiencing disease recurrence following surgery, despite adjuvant chemotherapy2The National Comprehensive Cancer Network® (NCCN®) Guidelines recommend routine testing for ALK, EGF
- Business Wire
FDA Approves Genentech's Alecensa as First Adjuvant Treatment for People With ALK-Positive Early-Stage Lung Cancer
SOUTH SAN FRANCISCO, Calif., April 18, 2024--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved Alecensa® (alectinib) for adjuvant treatment following tumor resection for patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) (tumors ≥ 4 cm or node positive), as detected by an FDA-approved test. Alecensa is now the first and only ALK inhibitor approved for people wi
